Logo image of ACIU

AC IMMUNE SA (ACIU) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ACIU - CH0329023102 - Common Stock

3.51 USD
-0.12 (-3.31%)
Last: 1/16/2026, 8:00:00 PM
3.5 USD
-0.01 (-0.28%)
After Hours: 1/16/2026, 8:00:00 PM
Fundamental Rating

2

ACIU gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. ACIU has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ACIU is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ACIU has reported negative net income.
  • ACIU had a negative operating cash flow in the past year.
  • ACIU had negative earnings in each of the past 5 years.
  • ACIU had negative operating cash flow in 4 of the past 5 years.
ACIU Yearly Net Income VS EBIT VS OCF VS FCFACIU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • ACIU has a Return On Assets (-41.88%) which is in line with its industry peers.
  • ACIU's Return On Equity of -115.10% is in line compared to the rest of the industry. ACIU outperforms 42.08% of its industry peers.
Industry RankSector Rank
ROA -41.88%
ROE -115.1%
ROIC N/A
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ACIU Yearly ROA, ROE, ROICACIU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ACIU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACIU Yearly Profit, Operating, Gross MarginsACIU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

  • ACIU does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ACIU has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ACIU has more shares outstanding
  • Compared to 1 year ago, ACIU has a worse debt to assets ratio.
ACIU Yearly Shares OutstandingACIU Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACIU Yearly Total Debt VS Total AssetsACIU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -3.14, we must say that ACIU is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -3.14, ACIU is in line with its industry, outperforming 46.42% of the companies in the same industry.
  • A Debt/Equity ratio of 0.06 indicates that ACIU is not too dependend on debt financing.
  • ACIU has a Debt to Equity ratio (0.06) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -3.14
ROIC/WACCN/A
WACC4.93%
ACIU Yearly LT Debt VS Equity VS FCFACIU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 1.16 indicates that ACIU should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.16, ACIU is not doing good in the industry: 85.09% of the companies in the same industry are doing better.
  • ACIU has a Quick Ratio of 1.16. This is a normal value and indicates that ACIU is financially healthy and should not expect problems in meeting its short term obligations.
  • ACIU's Quick ratio of 1.16 is on the low side compared to the rest of the industry. ACIU is outperformed by 84.34% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16
ACIU Yearly Current Assets VS Current LiabilitesACIU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

  • ACIU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -75.61%.
  • Looking at the last year, ACIU shows a very negative growth in Revenue. The Revenue has decreased by -89.33% in the last year.
  • The Revenue for ACIU have been decreasing by -24.39% on average. This is quite bad
EPS 1Y (TTM)-75.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-420%
Revenue 1Y (TTM)-89.33%
Revenue growth 3YN/A
Revenue growth 5Y-24.39%
Sales Q2Q%-96.32%

3.2 Future

  • The Earnings Per Share is expected to grow by 37.77% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ACIU will show a very strong growth in Revenue. The Revenue will grow by 55.36% on average per year.
EPS Next Y-37.31%
EPS Next 2Y-16.42%
EPS Next 3Y32.92%
EPS Next 5Y37.77%
Revenue Next Year-83.77%
Revenue Next 2Y9.92%
Revenue Next 3Y48.17%
Revenue Next 5Y55.36%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ACIU Yearly Revenue VS EstimatesACIU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
ACIU Yearly EPS VS EstimatesACIU Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • ACIU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ACIU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACIU Price Earnings VS Forward Price EarningsACIU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACIU Per share dataACIU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • ACIU's earnings are expected to grow with 32.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.42%
EPS Next 3Y32.92%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ACIU!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

AC IMMUNE SA

NASDAQ:ACIU (1/16/2026, 8:00:00 PM)

After market: 3.5 -0.01 (-0.28%)

3.51

-0.12 (-3.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-11
Inst Owners24.85%
Inst Owner Change-0.77%
Ins Owners3.4%
Ins Owner ChangeN/A
Market Cap352.44M
Revenue(TTM)4.37M
Net Income(TTM)-71.87M
Analysts88
Price Target9.86 (180.91%)
Short Float %5.77%
Short Ratio4.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.03%
Min EPS beat(2)-18%
Max EPS beat(2)17.94%
EPS beat(4)3
Avg EPS beat(4)6.34%
Min EPS beat(4)-18%
Max EPS beat(4)17.94%
EPS beat(8)5
Avg EPS beat(8)-0.9%
EPS beat(12)8
Avg EPS beat(12)-64.44%
EPS beat(16)10
Avg EPS beat(16)-69.05%
Revenue beat(2)1
Avg Revenue beat(2)-11.08%
Min Revenue beat(2)-35.35%
Max Revenue beat(2)13.19%
Revenue beat(4)3
Avg Revenue beat(4)57.1%
Min Revenue beat(4)-35.35%
Max Revenue beat(4)200.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.41%
PT rev (3m)7.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.86%
EPS NY rev (1m)0.13%
EPS NY rev (3m)8.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)17.13%
Revenue NY rev (1m)1.84%
Revenue NY rev (3m)9.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 64.62
P/FCF N/A
P/OCF N/A
P/B 4.52
P/tB 23.49
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.05
BVpS0.78
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.88%
ROE -115.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.15%
Cap/Sales 20.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z -3.14
F-Score2
WACC4.93%
ROIC/WACCN/A
Cap/Depr(3y)38.45%
Cap/Depr(5y)62.34%
Cap/Sales(3y)13.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-75.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-420%
EPS Next Y-37.31%
EPS Next 2Y-16.42%
EPS Next 3Y32.92%
EPS Next 5Y37.77%
Revenue 1Y (TTM)-89.33%
Revenue growth 3YN/A
Revenue growth 5Y-24.39%
Sales Q2Q%-96.32%
Revenue Next Year-83.77%
Revenue Next 2Y9.92%
Revenue Next 3Y48.17%
Revenue Next 5Y55.36%
EBIT growth 1Y-95.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.67%
EBIT Next 3Y-16.92%
EBIT Next 5Y-10.94%
FCF growth 1Y23.43%
FCF growth 3YN/A
FCF growth 5Y4.12%
OCF growth 1Y24.03%
OCF growth 3YN/A
OCF growth 5Y3.58%

AC IMMUNE SA / ACIU FAQ

Can you provide the ChartMill fundamental rating for AC IMMUNE SA?

ChartMill assigns a fundamental rating of 2 / 10 to ACIU.


Can you provide the valuation status for AC IMMUNE SA?

ChartMill assigns a valuation rating of 1 / 10 to AC IMMUNE SA (ACIU). This can be considered as Overvalued.


How profitable is AC IMMUNE SA (ACIU) stock?

AC IMMUNE SA (ACIU) has a profitability rating of 1 / 10.


What is the financial health of AC IMMUNE SA (ACIU) stock?

The financial health rating of AC IMMUNE SA (ACIU) is 2 / 10.


What is the expected EPS growth for AC IMMUNE SA (ACIU) stock?

The Earnings per Share (EPS) of AC IMMUNE SA (ACIU) is expected to decline by -37.31% in the next year.